September 2, 2021Purinergic Signalling46 citationsOpen Access

Recommended tool compounds and drugs for blocking P2X and P2Y receptors

CMChrista E. Müller VNVigneshwaran Namasivayam

Key Points

Key points are not available for this paper at this time.

Abstract

This review article presents a collection of tool compounds that selectively block and are recommended for studying P2Y and P2X receptor subtypes, investigating their roles in physiology and validating them as future drug targets. Moreover, drug candidates and approved drugs for P2 receptors will be discussed.

KI fragen

Bookmark

View Full Paper

Cite This Study

Müller et al. (2021) studied this question.

synapsesocial.com/papers/69d80c9066a29169b4bede50 https://doi.org/https://doi.org/10.1007/s11302-021-09813-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model2021 · 19 citations
2P2Y12 but not P2Y13 Purinergic Receptor Controls Postnatal Rat Retinogenesis In Vivo2018 · 7 citations
3P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo2013 · 38 citations
4Diabetes-induced Neuropathic Mechanical Hyperalgesia Depends on P2X4 Receptor Activation in Dorsal Root Ganglia2018 · 58 citations
5Identification and Biological Activity of the Active Metabolite of Clopidogrel2000 · 753 citations

KI fragen

Bookmark

View Full Paper